Deal Intelligence Platform & Services for Global M&A / PE
Oct 3 (Reuters) – Shares of LogicBio Therapeutics (LOGC.O) skyrocketed on Monday after Britain’s AstraZeneca’s (AZN.L) said it would buy the U.S.-based gene therapy developer at a rare 660% premium for $68 million.
Source
Author: unknown
Galderma Group AG agreed to acquire ZO Skin Health Inc. from Blackstone Tactical Opportunities and the Obagi family for an enterprise value of $1.5 billion. The all-cash transaction buys a...
BlackRock entered an agreement on October 13, 2026, to acquire the majority equity stake in a primary care joint venture from Welsh, Carson, Anderson & Stowe for $2.8 billion. The transaction...
STERIS Corporation, a wholly owned operating subsidiary of STERIS plc, agreed to buy Xodus Medical, Inc. for $2.1 billion in cash on October 12, 2026, according to a corporate press release...
Viatris Inc. agreed to purchase Pacira BioSciences Inc. for $36.50 per share in cash on October 8, 2026, establishing an equity valuation of approximately $1.65 billion. The transaction establishes...